Innoviva Inc (INVA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Respiratorysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 9.91% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Do Options Traders Know Something About Innoviva Stock We Don't?
- Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?
- INVA vs. MRK: Which Stock Is the Better Value Option?
- Should Value Investors Buy Innoviva (INVA) Stock?
- Innoviva to Participate in Upcoming Investor Conferences
- Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
- Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
- Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Innoviva Inc.
Full INVA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.